Renal Data

Less impact on markers of renal function across populations1-5

DESCOVY® had less long-term impact on markers of renal function vs FTC/TDF1-4

Median change in eGFRCG through Week 96

There was a 4.1 mL/min difference between DESCOVY FOR PrEP (+3.7 mL/min) and FTC/TDF (-0.4 mL/min) in eGFRCG at Week 96.2

The long-term clinical significance of changes in eGFR is not known.

Lower serum creatinine levels were also seen with DESCOVY FOR PrEP through Week 96

  • Median serum creatinine decreased 0.02 mg/dL with DESCOVY FOR PrEP vs a 0.01 mg/dL decreased with FTC/TDF from baseline at Week 96

eGFR remained steady over 144 weeks with DESCOVY®1-3

Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)

Median change in eGFR

Graph displaying DESCOVY® (emtricitabine/tenofovir alafenamide) median change in eGFR through week 144. See BOXED WARNING.

The long-term clinical significance of changes in eGFR is not known.

DESCOVY® had less long-term impact on eGFR in participants ≥50 years of age1,2,4,5

Results were seen in participants of an age group that may already be experiencing age-associated declines

Median change in eGFRCG in participants ≥50 years of age through Week 96

There was a 4.4-mL/min difference between DESCOVY FOR PrEP (+1.2 mL/min) and FTC/TDF (-3.2 mL/min) in eGFRCG at Week 96.4

The long-term clinical significance of changes in eGFR is not known.

DESCOVY FOR PrEP® can be used in people with impaired renal function of CrCl ≥30 mL/min.1

SEE BONE DATA FROM THE DISCOVER TRIAL

eGFRCG=estimated glomerular filtration rate (Cockcroft-Gault); FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; Q1, Q3=first quartile, third quartile.